Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHarvard Pilgrim Prior Auth Drug Coverage Update | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentharvard pilgrim health carePolicy N/A

    Prior Authorization Medical Necessity Guidelines — Part 1 (drug-specific PA rules)

    Customize your policy alerts

    Sign up for all harvard pilgrim health care policy alerts

    Know when harvard pilgrim health care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists prior authorization medical necessity criteria for multiple pharmacy and specialty drug products and defines required documentation, prescriber restrictions, coverage durations, and prerequisite therapy requirements for Harvard Pilgrim Health Care members.

    Policy Summary
    Payerharvard pilgrim health care
    PolicyPrior Authorization Medical Necessity Guidelines — Part 1 (drug-specific PA rules)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documented diagnosis, required prior-therapy trials or mutation testing, and specialist prescriber consultation where specified.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Multipleproducts listed in this section (partial)
    2 yearstypical coverage duration
    Variesprerequisite Part D drug
    Oftenspecialist prescriber required
    20+drugs with listed criteria in this segment

    Drug-Specific Coverage Criteria (A–Z excerpt)

    Abilify Mycite (selected criteria)

    Covered when ALL of the following are met

    Abilify Mycite initial criteria: Documented diagnosis of bipolar I disorder, major depressive disorder, or schizophrenia; documentation of worsening symptoms with oral aripiprazole;

    Prescriber must be a psychiatrist; Coverage duration: 2 years; Prerequisite: requires use of a prerequisite Part D drug.

    Abiraterone (selected criteria)

    Covered when ALL of the following are met

    Abiraterone criteria: Documented diagnosis of metastatic castration-resistant prostate cancer (CRPC) or metastatic high-risk castration-sensitive prostate cancer AND abiraterone is being used in combination with prednisone;

    Prescriber must be an oncologist or urologist; Coverage duration: 2 years; Prerequisite: does NOT require use of a prerequisite Part D drug.

    Policy Summary
    Payerharvard pilgrim health care
    PolicyPrior Authorization Medical Necessity Guidelines — Part 1 (drug-specific PA rules)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documented diagnosis, required prior-therapy trials or mutation testing, and specialist prescriber consultation where specified.
    SourceLink
    On This Page
    Drug-Specific Coverage Criteria (A–Z excerpt)Provider Requirements, Documentation & Denial TriggersCoding, Billing Notes & Indexed Drug ListInitial Authorization / First-Line RequirementsReauthorization / Continuation RequirementsStep Therapy / Prior-Therapy TablesSite-of-Care & Medicare Part B / Part D ConsiderationsKey Terms & DefinitionsPolicy Scope & BackgroundRevision History & Effective Dates

    Adalimumab family (selected criteria)

    Covered when ALL of the following are met (varies by indication)

    General adalimumab criteria: Documented diagnosis appropriate to indication (examples: ankylosing spondylitis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis with failed or intolerant to specified topical therapies, psoriatic arthritis, rheumatoid arthritis with trial/failure of one conventional therapy, polyarticular juvenile idiopathic arthritis with trial/failure of one conventional therapy, uveitis as specified);

    Prescriber must be or consult with relevant specialist (dermatologist, gastroenterologist, ophthalmologist, rheumatologist); Coverage duration: 2 years; Prerequisite: criteria may require use of a prerequisite Part D drug for some indications.

    Modafinil/Armodafinil (selected criteria)

    Covered when ALL of the following are met

    Wakefulness agents criteria: Documented diagnosis of narcolepsy, excessive sleepiness associated with obstructive sleep apnea, or shift-work sleep disorder;

    Coverage duration: 2 years; Exclusion: will not be approved for generalized fatigue, jet lag, or sleep-deprivation not associated with a covered diagnosis.

    Benlysta (belimumab) criteria

    Covered when ALL of the following are met

    Benlysta criteria: Documented diagnosis of active, autoantibody-positive systemic lupus erythematosus (SLE) or active lupus nephritis AND patient is concurrently taking standard therapy (eg, antimalarials, corticosteroids, or immunosuppressives);

    Prescriber must be a nephrologist or rheumatologist; Coverage duration: 2 years; Exclusions: not approved as monotherapy, for severe active lupus nephritis or severe active CNS lupus, for autoantibody-negative members, or in combination with other biologics or IV cyclophosphamide.

    Oncology: Medullary thyroid cancer

    Covered when ALL of the following are met for listed oncology agent entries

    Medullary thyroid cancer - cabozantinib/cometriq: Documented diagnosis of symptomatic or progressive medullary thyroid cancer with unresectable locally advanced or metastatic disease;

    Prescribing physician must be an endocrinologist or oncologist; Coverage duration: 2 years.

    Cayston

    Covered when ALL of the following are met for Cayston

    Cayston - cystic fibrosis: Documented diagnosis of cystic fibrosis AND evidence of Pseudomonas aeruginosa in the lungs;

    Coverage duration: 2 years.

    Dermatology / Rheumatology biologics

    Covered when ALL of the following are met for psoriasis, ankylosing spondylitis, RA and related indications

    Plaque psoriasis: Documented diagnosis of moderate-to-severe plaque psoriasis AND failure, contraindication, or intolerance to at least one specified topical therapy (eg, medium+ potency topical corticosteroid, vitamin D analog, tazarotene, calcineurin inhibitor, anthralin, coal tar);

    Prescribed by or in consultation with dermatologist; coverage 2 years.

    Rheumatoid arthritis / PJIA: Documented diagnosis of moderately to severely active rheumatoid arthritis OR polyarticular juvenile idiopathic arthritis AND trial and failure, contraindication, or intolerance to ONE conventional therapy (methotrexate, leflunomide, or sulfasalazine);

    Prescribed by or in consultation with rheumatologist; coverage 2 years.

    Non-radiographic axial spondyloarthritis / ERA: Documented diagnosis of active non-radiographic axial spondyloarthritis with objective signs of inflammation OR active enthesitis-related/ERA disease with trial/failure/contraindication/intolerance to two NSAIDs at maximally indicated doses for at least one month;

    Prescribed by or in consultation with dermatologist or rheumatologist; coverage 2 years.

    Dupixent (multiple indications)

    Covered when ALL of the following are met for Dupixent by indication

    Atopic dermatitis: Documented moderate-to-severe atopic dermatitis AND trial and failure (minimum 30 days) or contraindication/intolerance to at least one medium+ potency topical corticosteroid or listed topical alternatives;

    Prescribed by or in consultation with appropriate specialist (eg, allergist, dermatologist); coverage 2 years; Dupixent not for relief of acute bronchospasm or status asthmaticus.

    Asthma: Documented moderate-to-severe asthma with eosinophilic phenotype OR oral corticosteroid dependence;

    Specialist prescribing/consultation required; coverage 2 years.

    CRSwNP: Documented chronic rhinosinusitis with nasal polyposis inadequately controlled on current treatment;

    Specialist prescribing/consultation required; coverage 2 years.

    Ensacove - ALK+ NSCLC

    Covered when ALL of the following are met for Ensacove (ALK inhibitor)

    Ensacove - ALK+ NSCLC: Diagnosis of non-small cell lung cancer that is locally advanced or metastatic AND ALK rearrangement-positive AND patient has not previously received an ALK-inhibitor;

    Coverage duration: 2 years; approve continuation of prior therapy when applicable.

    Eltrombopag

    Covered when ALL of the following are met for Eltrombopag

    Eltrombopag indications: Persistent or chronic immune thrombocytopenic purpura (ITP) with insufficient response to corticosteroids, immunoglobulins, or splenectomy OR severe aplastic anemia in combination with standard immunosuppressive therapy OR thrombocytopenia with chronic hepatitis C;

    Coverage duration: 2 years.

    Exkivity — Initial Authorization

    Product-specific medical necessity requirements (examples from excerpt).

    Exkivity (mobocertinib): Documented locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutation AND progression on or after platinum-based chemotherapy;

    Prescriber must be an oncologist; Coverage duration: 2 years.

    Fasenra — Authorization Criteria

    Fasenra: Either: (1) severe eosinophilic asthma despite treatment with inhaled corticosteroid plus an additional controller (eg, LABA, leukotriene modifier, or sustained-release theophylline) OR (2) eosinophilic granulomatosis with polyangiitis (EGPA);

    Prescriber must be an asthma specialist or rheumatologist; prerequisite Part D drug required; Coverage duration: 2 years.

    Genotropin — Pediatric GHD Criteria

    Pediatric Growth Hormone (Genotropin entry): Member has not attained epiphyseal closure by X-ray AND failed to respond to at least two standard GH stimulation tests AND documented gender-specific delayed bone age AND height >2 SD below mean AND diagnosis consistent with listed pediatric GHD conditions (eg, chronic renal insufficiency, idiopathic short stature, Prader-Willi, Turner, SHOX deficiency);

    Continuation and re-evaluation criteria specified; coverage 2 years.

    Icatibant — Authorization Criteria

    Icatibant Acetate: Documented diagnosis of Hereditary Angioedema (HAE) with at least one severe attack in the past six months AND for HAE Types 1 & 2 diagnosis confirmed by laboratory testing (eg, low C4, reduced C1 esterase inhibitor level or function);

    Will not be approved for acquired angioedema or concurrent ACE inhibitor use; prescriber must be allergist, hematologist, or immunologist; coverage 2 years.

    Iclusig — Authorization Criteria

    Iclusig: Indications include: T315I-positive disease OR Philadelphia-chromosome positive ALL with no other TKI indicated OR accelerated/blast phase CML with no other kinase inhibitor indicated OR chronic phase CML with resistance/intolerance to at least two prior kinase inhibitors;

    Will not be approved for newly diagnosed chronic phase CML; prescriber must be hematologist/oncologist; coverage 2 years.

    Selected hematology/immune product criteria

    Products with specific required medical information and coverage duration

    Chronic GVHD: Documented diagnosis of chronic graft-versus-host disease after failure of one or two lines of systemic therapy;

    Coverage duration 2 years.

    Myelofibrosis: Documented diagnosis of intermediate- or high-risk myelofibrosis;

    Subsequent authorization requires documentation of spleen size reduction or symptomatic improvement; coverage 2 years.

    Polycythemia Vera: Documented diagnosis of polycythemia vera with inadequate response, contraindication, or intolerance to hydroxyurea;

    Coverage 2 years.

    Jubbonti (oncology) criteria

    Jubbonti (unnamed drug entry) hematologic oncology criteria

    MCL: Relapsed or refractory mantle cell lymphoma with at least two prior systemic therapies including a BTK inhibitor;

    Prescribed by or in consultation with an oncologist; coverage 2 years.

    CLL/SLL: Chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with a covalent BTK inhibitor;

    Prescribed by or in consultation with an oncologist; coverage 2 years.

    Jubbonti (denosumab) coverage criteria

    Jubbonti (denosumab) osteoporosis and other bone-loss indications

    Osteoporosis high risk: Member is at high risk of fracture OR has inadequate response/intolerance to at least one traditional osteoporosis treatment;

    Coverage 2 years.

    Breast cancer AI therapy: Female at high risk for fracture receiving aromatase inhibitor therapy who is using denosumab to increase bone mass;

    Coverage 2 years.

    Androgen deprivation: Men at high risk of fracture receiving androgen deprivation therapy for non-metastatic prostate cancer;

    Coverage 2 years.

    Glucocorticoid-induced osteoporosis: Treatment for glucocorticoid-induced osteoporosis in men and women at high risk for fracture;

    Coverage 2 years.

    Jynarque ADPKD criteria

    Jynarque (tolvaptan) ADPKD initiation and reauthorization criteria

    Diagnosis: Documented diagnosis of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD);

    Required for initiation.

    Liver monitoring (<=18 months): If received Jynarque <=18 months: ALT, AST, and bilirubin measured prior to initiation, at 2 and 4 weeks after initiation, then monthly for first 18 months;

    Patient must not have significant liver impairment.

    Liver monitoring (>18 months): If on Jynarque >18 months: ALT, AST, and bilirubin measured at least every 3 months;

    Patient must not have significant liver impairment except uncomplicated polycystic liver disease.

    Reauth response: For reauthorization: patient demonstrates positive clinical response and no signs/symptoms consistent with hepatic injury;

    Coverage duration 1 year.

    Kalydeco CF criteria

    Kalydeco (ivacaftor) cystic fibrosis criteria

    Diagnosis and genotype: Documented diagnosis of cystic fibrosis AND at least one CFTR mutation responsive to ivacaftor based on clinical and/or in vitro data (or FDA-cleared mutation test with sequencing when recommended);

    Granules: >=1 month of age; Kalydeco not effective for patients homozygous for F508del.

    Kesimpta criteria

    Kesimpta multiple sclerosis criteria

    Relapsing forms of MS: Documented diagnosis of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting, and active secondary progressive disease;

    Prescriber must be a neurologist; coverage 2 years.

    Kineret criteria

    Kineret indications and criteria

    RA initial: Diagnosis of moderately to severely active rheumatoid arthritis AND either trial/failure/contraindication/intolerance to two of the following (etanercept, a formulary adalimumab product, abatacept, upadacitinib, tofacitinib) OR attestation that trials are inappropriate OR continuation of prior therapy;

    Prescribed by or in consultation with a rheumatologist; coverage 1 year; prerequisite Part D drug required.

    NOMID initial: Diagnosis of neonatal-onset multisystem inflammatory disease (NOMID) AND confirmation by NLRP3 mutation OR clinical criteria (>=2 listed symptoms) plus elevated acute phase reactants;

    Prescribed by allergist/immunologist, rheumatologist, or pediatrician; coverage 1 year.

    Reauthorization: Patient demonstrates positive clinical response (eg, reduced swollen/tender joint count or symptom improvement for RA; clinical improvement for NOMID);

    Reauthorization per specified criteria.

    Koselugo criteria

    Koselugo neurofibromatosis type 1 criteria

    NF1 with plexiform neurofibromas: Documented diagnosis of neurofibromatosis type 1 AND symptomatic, inoperable plexiform neurofibromas;

    Patient >=1 year of age; prescriber neurologist or oncologist; coverage 2 years.

    Krazati criteria

    Krazati KRAS G12C-mutant cancer criteria

    NSCLC: KRAS G12C-mutated locally advanced or metastatic NSCLC with at least one prior systemic therapy;

    Prescribed by or in consultation with an oncologist; coverage 2 years; prerequisite Part D drug required.

    CRC: KRAS G12C-mutated locally advanced or metastatic colorectal cancer with prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy AND used in combination with cetuximab;

    Coverage 2 years; prescriber oncologist.

    Lapatinib criteria

    Lapatinib criteria for HER2-overexpressing breast cancer

    HER2+ advanced/metastatic breast cancer: Documented HER2-overexpressing advanced/metastatic breast cancer; prior failure of anthracycline and taxane therapy and prior trastuzumab; concurrent treatment with capecitabine;

    Prescriber must be an oncologist; coverage 2 years; prerequisite Part D drug required.

    HR+ metastatic in postmenopausal women: Hormone receptor positive metastatic breast cancer overexpressing HER2 and concurrently treated with letrozole;

    Prescriber oncologist; coverage 2 years.

    Lazcluze criteria

    Lazcluze (mobocertinib) with amivantamab criteria

    Lazcluze with amivantamab: NSCLC locally advanced or metastatic used as first-line treatment in combination with amivantamab AND presence of EGFR exon 19 deletions or exon 21 L858R substitution mutations;

    Coverage 2 years; approve continuation of prior therapy.

    Lenalidomide criteria

    Lenalidomide hematologic and oncologic criteria

    Follicular Lymphoma: Previously treated follicular lymphoma used in combination with rituximab;

    Prescriber hematologist/oncologist; coverage 2 years.

    Mantle Cell Lymphoma: Relapsed or progressed mantle cell lymphoma after two prior therapies, one including bortezomib;

    Coverage 2 years.

    Marginal Zone Lymphoma: Previously treated marginal zone lymphoma used with rituximab;

    Coverage 2 years.

    Multiple Myeloma: Documented multiple myeloma used with dexamethasone or as maintenance post-autologous HSCT;

    Coverage 2 years.

    MDS 5q: Transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with 5q deletion cytogenetic;

    Coverage 2 years.

    Lenvima criteria

    Lenvima (lenvatinib) oncology criteria

    Advanced endometrial carcinoma that is pMMR/non-MSI-H with disease progression following prior systemic therapy and not candidate for curative surgery/radiation AND used with pembrolizumab;

    Prescriber oncologist; coverage 2 years.

    Advanced renal cell carcinoma: either has had one prior antiangiogenic therapy and used with everolimus OR first-line in combination with pembrolizumab;

    Coverage 2 years.

    Hepatocellular carcinoma: Unresectable hepatocellular carcinoma;

    Coverage 2 years.

    Thyroid cancer: Locally recurrent/metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer;

    Coverage 2 years.

    Lidocaine patch criteria

    Lidocaine transdermal patch criteria

    PHN or diabetic neuropathy: Postherpetic neuralgia or diabetic neuropathy with failure, adverse reaction, or contraindication to gabapentin OR member not candidate for opioid/oral pain management; new members approved if currently well-controlled on patches;

    Coverage 2 years.

    Livtencity criteria

    Livtencity (maribavir) CMV criteria

    Post-transplant CMV refractory: Member >=35 kg with documented post-transplant CMV infection/disease refractory to ganciclovir, valganciclovir, cidofovir, or foscarnet (with or without genotypic resistance);

    Coverage 2 years.

    Lonsurf criteria

    Lonsurf metastatic cancer criteria

    mCRC: Metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy;

    Prescriber must be oncologist; coverage 2 years.

    Metastatic gastric/GEJ adenocarcinoma: Previously treated with at least two prior lines including fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate HER2-targeted therapy;

    Coverage 2 years; prescriber oncologist.

    Lorbrena criteria

    Lorbrena (lorlatinib) ALK+ NSCLC criteria

    ALK+ NSCLC: Documented metastatic non-small cell lung cancer with ALK-positive tumor;

    Prescriber must be oncologist; coverage 2 years.

    Lumakras criteria

    Lumakras (sotorasib) KRAS G12C criteria

    NSCLC KRAS G12C: KRAS G12C-mutated locally advanced or metastatic NSCLC with at least one prior systemic therapy;

    Prescriber must be oncologist; coverage 2 years; prerequisite Part D drug required.

    mCRC KRAS G12C: KRAS G12C-mutated metastatic colorectal cancer used in combination with panitumumab and prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy;

    Coverage 2 years.

    Lybalvi criteria

    Lybalvi psychiatric indications

    Schizophrenia or Bipolar I: Documented diagnosis of schizophrenia or Bipolar I disorder;

    Prescriber must be a psychiatrist; coverage 2 years.

    Lynparza criteria

    Lynparza (olaparib) oncologic indications

    Breast cancer: Deleterious or suspected deleterious germline BRCA-mutated HER2-negative metastatic breast cancer treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting AND if HR+, prior endocrine therapy or contraindication/intolerance to endocrine therapy OR high-risk early breast cancer treated with neoadjuvant or adjuvant chemotherapy;

    Prescriber must be an oncologist; coverage 2 years; prerequisite Part D drug required.

    Ovarian cancer maintenance: Maintenance for deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian/fallopian tube/primary peritoneal cancer in complete/partial response to first-line platinum chemotherapy OR maintenance in combination with bevacizumab for HRD-positive disease in complete/partial response OR maintenance of recurrent disease in response to platinum-based chemotherapy;

    Coverage 2 years.

    Pancreatic BRCA: Deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma with no progression after >=16 weeks of first-line platinum-based chemotherapy;

    Coverage 2 years.

    Prostate HRR mutated: Deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC progressed after enzalutamide or abiraterone OR BRCAm mCRPC used with abiraterone and prednisone/prednisolone;

    Coverage 2 years.

    Lynparza - Indications and Required Information

    Covered for specified oncology indications when ALL required conditions for each indication are met:

    Lynparza indications summary: Meets any of the enumerated Lynparza indication-specific condition sets (eg, metastatic BRCA-mutated breast, maintenance ovarian indications, pancreatic BRCA after platinum chemotherapy, HRR-mutated mCRPC after prior AR-targeted therapy, etc.);

    Prescriber must be an oncologist; coverage duration 2 years; requires Part D prerequisite drug where indicated.

    Lytgobi - Indications and Required Information

    Covered when ALL of the following are met:

    Lytgobi indication: Documented diagnosis of previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or rearrangements;

    Prescribed by or in consultation with an oncologist; coverage 2 years.

    Pulmonary hypertension agents (selected)

    Covered when ALL required diagnostic confirmations are present:

    PAH/CTEPH indications: Pulmonary arterial hypertension confirmed by right heart catheterization OR chronic thromboembolic pulmonary hypertension that is persistent/recurrent after surgical treatment or inoperable;

    Prescriber must be a cardiologist or pulmonologist; coverage 2 years.

    Nexletol/Nexlizet - Lipid indications

    Covered when ALL of the following are met:

    Nexletol/Nexlizet criteria: Elevated LDL-C while on maximally tolerated statin therapy OR elevated LDL-C with contraindication/intolerance to statins; AND diagnosis of HeFH OR atherosclerotic cardiovascular disease OR established CVD OR high risk for CVD without established disease;

    Prescribed by or in consultation with cardiologist, endocrinologist, lipidologist, or neurologist; coverage 2 years; requires Part D prerequisite drug.

    Orserdu (example)

    Covered when ALL of the following are met

    Orserdu: Diagnosis of advanced or metastatic ER-positive, HER2-negative breast cancer with documented ESR1 mutation AND disease progressed following at least one line of endocrine therapy;

    Prescribed by or in consultation with an oncologist; coverage 2 years; prerequisite Part D drug required.

    Otezla

    Covered when ALL of the following are met

    Otezla: Psoriatic arthritis: documented diagnosis; Plaque psoriasis: documented moderate-to-severe disease with failure or intolerance to at least one listed topical therapy; Oral ulcers in Behcet's: documented active oral ulcers;

    Prescribed by or in consultation with dermatologist or rheumatologist; coverage 2 years; prerequisite Part D drug required.

    Piqray

    Covered when ALL of the following are met

    Piqray: Documented hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer AND disease progressed on or after an endocrine-based regimen AND Piqray will be used in combination with fulvestrant;

    Prescribing physician must be an oncologist; coverage 2 years; prerequisite Part D drug required.

    Rezdiffra (MASH/NASH)

    Initial authorization covered when ALL of the following are met

    Rezdiffra initial: Diagnosis of metabolic dysfunction-associated steatohepatitis (MASH/NASH) without cirrhosis; fibrosis stage F2 or F3 confirmed by specified serum and imaging biomarkers or liver biopsy within past 12 months; presence of >=1 metabolic risk factor (eg, T2DM, hypertension, obesity);F2 or F3

    Prescribed by or in consultation with gastroenterologist or hepatologist; coverage 2 years; reauthorization requires positive response and no progression to cirrhosis.

    Rinvoq

    Covered for multiple indications with indication-specific preconditions

    Rinvoq indications: Any of the listed Rinvoq indications (eg, ankylosing spondylitis, atopic dermatitis refractory moderate-to-severe, psoriatic arthritis after TNF inhibitor failure, rheumatoid arthritis with prior conventional therapy failure and inadequate response to TNF inhibitors, ulcerative colitis/Crohn's disease with inadequate response/intolerance to TNF inhibitors or other systemic therapy);

    Prescribed by or in consultation with appropriate specialists; coverage 2 years; prerequisite Part D drug required where specified.

    Rydapt: Covered when ALL are met

    Rydapt (midostaurin) coverage conditions

    Rydapt initial therapy criteria: Documented acute myeloid leukemia (AML) that is FLT3 mutation-positive AND Rydapt is being used as first-line therapy in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation;

    Prescribing physician must be a hematologist, oncologist, or allergist; Coverage duration 2 years; Rydapt will not be approved as single-agent induction therapy.

    TIRF: Covered when ALL are met

    Transmucosal Immediate-Release Fentanyl (TIRF) coverage conditions

    TIRF cancer breakthrough pain: Adult cancer patient with breakthrough pain who is opioid-tolerant AND already receiving around-the-clock opioid therapy AND prescriber is an oncologist or pain management specialist;Patients considered opioid tolerant as defined

    Patients must remain on around-the-clock opioids when taking TIRF; TIRF not covered for non-cancer pain.

    Trikafta: Covered when ALL are met

    Trikafta (CFTR modulator) coverage conditions

    Trikafta initial and reauthorization: Initial: diagnosis of cystic fibrosis with at least one eligible CFTR mutation (eg, F508del or other responsive mutation) AND appropriate age per formulation (granules 2 to <6 years; tablets >=6 years) AND prescribed by or in consultation with pulmonologist or CF center specialist; Reauth: evidence of clinical benefit (eg, PPFEV1 improvement or decreased pulmonary exacerbations);Age thresholds per formulation

    Coverage duration 2 years.

    Truqap: Covered when ALL are met

    Truqap (alpelisib) coverage conditions

    Truqap breast cancer criteria: Documented HR-positive, HER2-negative locally advanced or metastatic breast cancer AND tumor has one or more PIK3CA/AKT1/PTEN alterations AND will be used in combination with fulvestrant AND disease progressed following at least one endocrine-based regimen or recurred within 12 months of adjuvant therapy;

    Coverage duration 2 years; requires prerequisite Part D drug.

    Biologics: Covered when ALL are met

    Biologic agents for dermatologic, rheumatologic, and GI indications

    Skyrizi and similar biologics: Documented diagnosis appropriate to indication (eg, moderate-to-severe plaque psoriasis with failure/intolerance to topical agents; psoriatic arthritis; moderate-to-severe Crohn's disease; moderately-to-severely active ulcerative colitis) AND trial/failure or intolerance to specified prior therapies where required;

    Prescribed by or in consultation with relevant specialist; coverage 2 years; prerequisite Part D drug required for some indications.

    Stelara criteria: Documented diagnosis appropriate to indication AND trial/intolerance/contraindication to Yesintek or Steqeyma where required;

    Prescribed by or in consultation with dermatologist, gastroenterologist, or rheumatologist; coverage 2 years.

    Truqap (CF) Initial

    Truqap (Cystic Fibrosis) — Covered when ALL of the following are met

    Truqap initial (CF): Diagnosis of cystic fibrosis AND patient has at least one of the following CFTR mutations: F508del OR another mutation responsive based on clinical/in vitro data AND formulation age restriction satisfied (granules 2 to <6 years OR tablets >=6 years) AND prescribed by or in consultation with a pulmonologist or CF care center specialist;

    Coverage duration 2 years.

    Tukysa (alpelisib) criteria

    Tukysa — Covered when ALL of the following are met

    Tukysa for specified breast cancer: Documented locally advanced or metastatic HR-positive, HER2-negative breast cancer AND presence of one or more PIK3CA/AKT1/PTEN alterations AND progression on at least one endocrine-based regimen in the metastatic setting OR recurrence within 12 months of adjuvant therapy AND drug will be taken in combination with fulvestrant;

    Coverage duration 2 years; prerequisite Part D drug required.

    Turalio (pexidartinib) criteria

    Turalio — Covered when ALL of the following are met

    Turalio for TGCT: Documented symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations AND condition not amenable to improvement with surgery;

    Coverage duration 2 years.

    Rheumatology / pulmonary agent criteria

    Agents listed (e.g., biologics, immunomodulators) — Covered when specified indication-specific conditions are met

    RA initial for listed agent: Diagnosis of moderately to severely active rheumatoid arthritis AND either trial/failure/contraindication/intolerance to two specified agents (eg, Enbrel, formulary adalimumab, Orencia, Rinvoq, Xeljanz) OR attestation that trials inappropriate OR continuation of prior therapy;

    Prescriber rheumatologist; coverage 1 year; prerequisite Part D drug required where specified.

    SSc-ILD: Diagnosis of systemic sclerosis-associated interstitial lung disease documented by exclusion of other causes AND HRCT or biopsy pattern consistent with SSc-ILD as specified;

    Prescribed by pulmonologist or rheumatologist; coverage 1 year.

    Voquezna (vonoprazan) criteria

    Voquezna (various packs) — Covered when ALL of the following are met (indication-specific)

    Voquezna for H. pylori (Dual/Triple Pak): Diagnosis of H. pylori infection AND trial and failure, contraindication, or intolerance to bismuth quadruple therapy;

    Coverage duration per pack (eg, 1 month).

    Voquezna for erosive esophagitis (HRH): Diagnosis of erosive esophagitis AND trial and inadequate response, contraindication, or intolerance to TWO generic PPIs;

    HRH coverage 2 months; maintenance coverage per indication.

    Voquezna for NERD relief: Diagnosis of non-erosive GERD with history of heartburn >=6 months and symptoms at least 4 days in any consecutive 7-day period AND trial and inadequate response, contraindication, or intolerance to TWO generic PPIs;

    Coverage duration per indication.

    Vyndamax criteria

    Vyndamax (tafamidis) — Covered when ALL of the following are met

    Vyndamax for ATTR-CM: Documented transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) AND one of: presence of a TTR mutation OR biopsy showing TTR amyloid deposits OR supportive cardiac imaging suggestive of amyloidosis; AND absence of light-chain amyloidosis AND documentation of NYHA Functional Class I–III heart failure;

    Prescribed by a cardiologist; coverage per plan year; reauth requires continued NYHA I–III.

    Wyost (denosumab) criteria

    Wyost (denosumab) — Covered when ANY of the following are met

    Wyost coverage scenarios: (1) Prevention of skeletal-related events in patients with multiple myeloma or bone metastases from solid tumors; OR (2) Treatment of unresectable giant cell tumor of bone (GCTB) or when surgical resection likely to result in severe morbidity; OR (3) Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy;

    Coverage duration 2 years; prerequisite Part D drug required.

    Wyost (denosumab) - oncology indications

    Coverage authorized when ONE of the following is met:

    Wyost indications (oncology): 1) Prevention of skeletal-related events in multiple myeloma or bone metastases from solid tumors; 2) Treatment of unresectable GCTB or when surgical resection likely causes severe morbidity; 3) Treatment of hypercalcemia of malignancy refractory to bisphosphonates;

    Coverage duration 2 years; prerequisite Part D drug required.

    Xalkori (crizotinib)

    Coverage authorized when ANY of the following documented diagnoses are present:

    Xalkori indications: 1) Metastatic NSCLC that is ALK-positive or ROS1-positive; 2) Relapsed/refractory systemic ALCL that is ALK-positive; 3) Unresectable, recurrent, or refractory IMT that is ALK-positive;

    Prescribing physician must be an oncologist; coverage 2 years.

    Xolair (omalizumab)

    Coverage authorized when criteria for the specific indication are met:

    Xolair - Asthma (example): Moderate-to-severe persistent asthma with failure of regimen including two or more of inhaled corticosteroids, oral corticosteroids, leukotriene modifiers, and long-acting bronchodilators; definitive sensitivity to perennial allergens; pre-treatment serum IgE 30–1,300 IU/mL;IgE 30-1300 IU/mL

    Prescriber must be allergist/immunologist or pulmonologist; coverage 2 years; prerequisite Part D drug required.

    Chronic Spontaneous Urticaria: Documented CSU with continued symptoms despite H1 antihistamine treatment;

    Coverage per indication.

    Nasal polyps: Documented nasal polyps with inadequate response to nasal corticosteroids;

    Coverage per indication.

    Xpovio (selinexor) in multiple myeloma and DLBCL

    Coverage authorized for specified regimens when ALL listed criteria are met:

    Xpovio with dexamethasone: Relapsed or refractory multiple myeloma AND at least four prior therapies AND disease refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody;

    Prescriber must be a hematologist/oncologist; coverage 2 years; prerequisite Part D drug required.

    Xpovio with bortezomib and dexamethasone: Multiple myeloma AND at least one prior therapy;

    Coverage per indication.

    Xpovio for DLBCL: Relapsed or refractory diffuse large B-cell lymphoma after at least two lines of systemic therapy;

    Coverage per indication.

    Zejula (niraparib)

    Coverage authorized when ONE of the following is met:

    Zejula maintenance: Advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer with complete or partial response to platinum-based chemotherapy;

    Prescriber must be an oncologist; coverage 2 years; prerequisite Part D drug required.

    BRCA-mutated recurrent disease: Recurrent epithelial ovarian/fallopian tube/primary peritoneal cancer with deleterious or suspected deleterious germline BRCA mutation in complete or partial response to platinum-based chemotherapy;

    Coverage per indication.

    Zelboraf (vemurafenib)

    Coverage authorized when ANY of the following is met:

    Zelboraf indications: Erdheim-Chester Disease with BRAF V600 mutation OR unresectable/metastatic melanoma that is BRAF V600E mutation-positive;

    Prescriber must be an oncologist/hematologist; coverage 2 years; not indicated for wild-type BRAF melanoma.

    Ztalmy (fenfluramine)

    Coverage authorized when the following is met:

    Ztalmy (fenfluramine): Diagnosis of seizures associated with CDKL5 deficiency disorder (CDD);

    Prescribed by or in consultation with a neurologist; coverage 2 years.

    Zydelig (idelalisib) for CLL

    Coverage authorized when the following is met:

    Zydelig for CLL: Relapsed chronic lymphocytic leukemia (CLL) when used in combination with rituximab;

    Prescriber must be a hematologist/oncologist; coverage 2 years.

    Steqeyma / Yesintek (adalimumab biosimilars) - multiple indications

    Coverage authorized when indication-specific criteria are met:

    Steqeyma / Yesintek indications: Moderately to severely active Crohn's disease OR moderate-to-severe plaque psoriasis with failure/intolerance to topical therapies OR psoriatic arthritis/ulcerative colitis per indication-specific criteria;

    Prescribed by or in consultation with dermatologist, gastroenterologist, or rheumatologist; coverage 2 years; prerequisite Part D drug required for some indications.

    Xermelo (telotristat) for carcinoid syndrome diarrhea

    Coverage authorized when the following is met:

    Xermelo for carcinoid syndrome diarrhea: Documented carcinoid syndrome diarrhea inadequately controlled by somatostatin analog (SSA) therapy alone AND Xermelo will be used in combination with an SSA;

    Prescriber must be gastroenterologist, hematologist, or oncologist; coverage 2 years; prerequisite Part D drug required.

    Xdemvy (lotilaner) for Demodex blepharitis

    Coverage authorized when the following is met:

    Xdemvy for Demodex blepharitis: Documented diagnosis of Demodex blepharitis;

    Medication must be prescribed by or in consultation with an ophthalmologist or optometrist; coverage 2 years.

    Provider Requirements, Documentation & Denial Triggers

    Prior Authorization

    Adalimumab family prior authorization

    Prior authorization is required for medications in the adalimumab product family for all listed indications. Prescriptions should be written by or in consultation with the appropriate specialist (dermatologist, gastroenterologist, ophthalmologist or rheumatologist) when indicated. Document the specific diagnosis, prior topical/systemic therapy trials where applicable (e.g., psoriasis, hidradenitis suppurativa, rheumatoid arthritis), and trial/failure, contraindication, or intolerance to required conventional therapies (e.g., methotrexate, leflunomide, sulfasalazine for RA). Coverage duration is typically 2 years. Missing documentation of required prior therapy, specialist consultation, or indication may result in denial.

    • Products: Humira and biosimilars listed under Adalimumab family
    • Prescriber restriction: dermatologist, gastroenterologist, ophthalmologist, or rheumatologist as appropriate
    • Required documentation: diagnosis, prior therapy trials and failures/intolerance/contraindication
    • Coverage duration: 2 years
    Prior Authorization

    Abiraterone prior authorization

    Prior authorization required for abiraterone acetate when used for metastatic castration-resistant prostate cancer (CRPC) or metastatic high-risk castration-sensitive prostate cancer. Must be prescribed by an oncologist or urologist and used in combination with prednisone. Document the diagnosis and that the drug will be given with prednisone. Coverage duration is 2 years.

    • Products: Abiraterone acetate (Yonsa, etc.)
    • Prescriber restriction: oncologist or urologist
    • Required documentation: metastatic CRPC or high-risk castration-sensitive prostate cancer; confirmation of combination with prednisone
    • Coverage duration: 2 years
    Prior Authorization

    Akeega prior authorization

    Prior authorization required for Akeega (for BRCA-mutated prostate cancer). Prescriber must be an oncologist. Document metastatic prostate cancer with deleterious or suspected deleterious BRCA mutation (BRCA1/BRCA2 as specified), use in combination with prednisone, and either use with a GnRH analog or evidence the patient has had bilateral orchiectomy. Coverage duration is 2 years.

    • Products: Akeega
    • Prescriber restriction: oncologist
    • Required documentation: metastatic disease, deleterious/suspected deleterious BRCA mutation, concurrent prednisone, GnRH analog use or orchiectomy
    • Coverage duration: 2 years
    Prior Authorization

    Cabozantinib (Cometriq) prior authorization — medullary thyroid cancer

    Prior authorization is required for cabozantinib (Cometriq) when used for medullary thyroid cancer. Prescriber should be an oncologist or endocrinologist. Document progressive, metastatic medullary thyroid cancer and unresectable locally advanced or metastatic disease. Coverage duration typically 2 years. Lack of documentation of progression or unresectability may lead to denial.

    • Products: Cometriq (cabozantinib)
    • Prescriber restriction: oncologist or endocrinologist
    • Required documentation: progressive, unresectable locally advanced or metastatic medullary thyroid cancer
    • Coverage duration: 2 years
    Prior Authorization

    Cayston prior authorization — cystic fibrosis with Pseudomonas

    Prior authorization required for Cayston (aztreonam) for cystic fibrosis. Document a diagnosis of CF and evidence of Pseudomonas aeruginosa in the lungs (sputum culture or other microbiologic evidence). Coverage duration generally 2 years. Missing microbiology or CF diagnosis documentation risks denial.

    • Products: Cayston (aztreonam)
    • Required documentation: confirmed cystic fibrosis diagnosis and presence of Pseudomonas aeruginosa in respiratory secretions
    • Coverage duration: 2 years
    Prior Authorization

    Dupixent prior authorization and specialty prescribing

    Dupixent requires prior authorization for its labeled indications. Prescriptions should be by or in consultation with an appropriate specialist (allergist, dermatologist, immunologist, otolaryngologist, pulmonologist, or gastroenterologist). For atopic dermatitis and other dermatologic indications document trial and failure, contraindication, or intolerance to required topical/systemic therapies as specified. Dupixent is not approved for relief of acute bronchospasm or status asthmaticus. Coverage duration is 2 years.

    • Products: Dupixent
    • Prescriber restriction: allergist, dermatologist, immunologist, otolaryngologist, pulmonologist, or gastroenterologist
    • Required documentation: indication-specific prior topical/systemic therapy trials and failures/intolerance
    • Exclusion: not for acute bronchospasm or status asthmaticus
    • Coverage duration: 2 years
    Prior Authorization

    Ensacove prior authorization — ALK+ NSCLC, ALK-inhibitor naive

    Ensacove (for ALK-positive NSCLC) requires prior authorization. Document ALK rearrangement-positive locally advanced or metastatic NSCLC and that the patient is ALK-inhibitor naïve (no prior ALK inhibitor therapy such as alectinib, brigatinib, lorlatinib, crizotinib, ceritinib). Prescriber should be an oncologist. Coverage duration is 2 years.

    • Products: Ensacove
    • Required documentation: ALK-positive NSCLC; locally advanced or metastatic disease; no prior ALK-inhibitor exposure
    • Prescriber restriction: oncologist
    • Coverage duration: 2 years
    Documentation Required

    Jynarque prior authorization and liver monitoring

    Prior authorization and liver monitoring are required for Jynarque (tolvaptan) in ADPKD. For initiation document diagnosis of rapidly progressing ADPKD. Liver tests (ALT, AST, bilirubin) must be measured prior to initiation, at 2 and 4 weeks after initiation, then monthly for the first 18 months; for patients on therapy longer than 18 months, monitor ALT/AST/bilirubin at least every 3 months. Patients with significant liver impairment or injury are excluded. Coverage duration is 1 year for initial authorization; reauthorization requires clinical response and continued appropriate lab monitoring.

    • Products: Jynarque (tolvaptan)
    • Required documentation: diagnosis of rapidly progressing ADPKD
    • Monitoring: ALT, AST, bilirubin prior to initiation, at 2 and 4 weeks, then monthly for 18 months; thereafter at least every 3 months if continued
    • Exclusion: history of significant liver impairment/injury (except uncomplicated polycystic liver disease)
    • Coverage duration: 1 year (initial)
    Denial Risk

    Jubbonti (denosumab) prior authorization and denial triggers

    Denosumab products used for osteoporosis (Jubbonti) require prior authorization and specific indication documentation. Approvals require the member to be at high risk of fracture or have had inadequate response or intolerance to traditional osteoporosis therapies (e.g., alendronate, ibandronate, risedronate, zoledronic acid) or be receiving aromatase inhibitor therapy with high fracture risk. Denosumab used for oncology indications (prevention of skeletal-related events, unresectable giant cell tumor of bone, hypercalcemia of malignancy refractory to bisphosphonates) must have supporting oncology documentation. Missing indication or prior therapy documentation may trigger denial.

    • Products: Jubbonti (denosumab) and Wyost
    • Required documentation (osteoporosis): high fracture risk OR inadequate response/intolerance to traditional therapies
    • Required documentation (oncology): evidence of bone metastases, multiple myeloma, unresectable GCTB, or hypercalcemia of malignancy as applicable
    • Coverage duration: 2 years
    • Denial risk: requests lacking indication or prior therapy documentation
    Prior Authorization

    Pulmonary hypertension drugs prior authorization

    Pulmonary hypertension agents require prior authorization. For pulmonary arterial hypertension, document diagnosis confirmed by right heart catheterization. For chronic thromboembolic pulmonary hypertension (CTEPH), document persistent or recurrent CTEPH after surgical treatment or inoperable disease. Prescriber should be a cardiologist or pulmonologist. Coverage duration is typically 2 years. Failure to submit hemodynamic confirmation or persistent/recurrent disease documentation may delay or prevent approval.

    • Products: PAH agents (e.g., Adempas, Opsumit, Orenitram, ambrisentan, bosentan, sildenafil, tadalafil, epoprostenol formulations)
    • Required documentation: right heart catheterization confirming PAH or documentation of persistent/recurrent CTEPH
    • Prescriber restriction: cardiologist or pulmonologist
    • Coverage duration: 2 years
    Prior Authorization

    Rinvoq prior authorization — failure/intolerance to specified therapies required

    Rinvoq (upadacitinib) prior authorization is required. Document diagnosis-specific criteria including prior topical/systemic therapy trials where applicable and failure/intolerance to specified therapies (e.g., conventional DMARDs, TNF inhibitors) per indication. Prescribe by or in consultation with appropriate specialty (e.g., rheumatologist, dermatologist, gastroenterologist). Coverage duration is 2 years.

    • Products: Rinvoq (tablets and liquid)
    • Required documentation: indication-specific prior therapy failures/intolerance (see indication details)
    • Prescriber restriction: appropriate specialist (rheumatology, dermatology, gastroenterology, allergist/immunologist)
    • Coverage duration: 2 years
    Prior Authorization

    TIRF prior authorization — opioid-tolerant adult cancer patients only

    Transmucosal immediate-release fentanyl (TIRF) products are limited to opioid-tolerant adult cancer patients for breakthrough pain and require prior authorization. Prescriber must be an oncologist or pain management specialist. Patients must be opioid tolerant (document around-the-clock opioid regimen meeting equianalgesic thresholds) and must remain on around-the-clock opioids while using TIRF. TIRF products are not covered for non-cancer pain. Coverage duration typically 2 years.

    • Products: TIRF (transmucosal immediate-release fentanyl formulations)
    • Indication: adult cancer patients who are opioid tolerant; pediatric approval limited (e.g., lozenges for ≥16 years)
    • Required documentation: opioid tolerance (example equianalgesic thresholds) and prescriber specialty
    • Exclusion: not covered for non-cancer pain
    • Coverage duration: 2 years
    Denial Risk

    Explicit denials / exclusions for non-covered uses

    Some drugs are explicitly not covered for non-indicated uses. Armodafinil/modafinil will be denied for generalized fatigue, jet lag, or sleep deprivation not associated with a covered diagnosis. Quinine sulfate will not be approved for nocturnal leg cramps. Tadalafil is excluded for erectile dysfunction. Failure to match the requested use to an approved indication will result in denial.

    • Armodafinil/modafinil: not approved for generalized fatigue, jet lag, or non-covered sleep disorders
    • Quinine sulfate: not approved for nocturnal leg cramps
    • Tadalafil: excluded for erectile dysfunction
    Denial Risk

    Benlysta explicit exclusions

    Benlysta (belimumab) will not be approved as monotherapy, for members with severe active lupus nephritis or severe active CNS lupus, for autoantibody-negative patients, or in combination with other biologics or intravenous cyclophosphamide. Prescriber should be a nephrologist or rheumatologist and documentation of active, autoantibody-positive SLE or active lupus nephritis with concurrent standard therapy must be submitted.

    • Products: Benlysta (belimumab)
    • Exclusions: monotherapy, severe active lupus nephritis or CNS lupus, autoantibody-negative patients, combination with other biologics/IV cyclophosphamide
    • Required documentation: active, autoantibody-positive SLE or active lupus nephritis plus concurrent standard therapy
    • Prescriber restriction: nephrologist or rheumatologist
    • Coverage duration: 2 years
    Denial Risk

    Icatibant non-approval scenarios and required documentation

    Icatibant will not be approved for acquired angioedema or for patients concurrently taking ACE inhibitors. For hereditary angioedema, documentation of diagnosis and at least one severe attack in the past six months is required; HAE Types 1 & 2 must be confirmed by laboratory testing (low C4, reduced C1 esterase inhibitor level or function). Prescriber should be an allergist, hematologist, or immunologist.

    • Products: Icatibant
    • Exclusions: acquired angioedema; concurrent ACE inhibitor therapy
    • Required documentation: HAE diagnosis and recent severe attack; lab confirmation for HAE Types 1 & 2
    • Prescriber restriction: allergist, hematologist, or immunologist
    Denial Risk

    Iclusig non-approval scenarios and required documentation

    Iclusig (ponatinib) will not be approved for newly diagnosed chronic phase CML. Indications approved require T315I-positive disease or resistant/intolerant disease after prior kinase inhibitors as detailed in the policy; prescriber should be a hematologist or oncologist. Documentation of mutation status and prior therapies is required.

    • Products: Iclusig (ponatinib)
    • Exclusion: newly diagnosed chronic phase CML
    • Required documentation: T315I mutation status or evidence of resistance/intolerance to prior kinase inhibitors
    • Prescriber restriction: hematologist or oncologist
    Denial Risk

    Concurrent therapy exclusion — confirm allowable combinations

    Concurrent therapy exclusions: certain agents (e.g., Rubraca) are not approvable for concurrent use with other chemotherapy agents unless specified. Verify concurrent therapy is allowed per the indication and submit supporting documentation. Requests for explicitly excluded concurrent combinations may be denied.

    • Products: Rubraca and others with concurrent therapy restrictions
    • Action: confirm allowable combinations; provide documentation if concurrent use is requested
    • Denial risk: requests for excluded concurrent combinations
    Step Therapy

    Prior therapy exclusions and step-therapy requirements

    Prior therapy exclusions and step therapy requirements are enforced across multiple products. Examples: Mekinist will not be approved as single agent after prior BRAF inhibitor therapy; Rezurock requires trial and failure of two or more systemic therapies for chronic GVHD; Kineret and other rheumatologic agents require documented prior conventional therapy trials. Ensure documentation of required prior trials, failures, contraindications, or intolerances is included.

    • Mekinist: not as single agent after prior BRAF inhibitor therapy
    • Rezurock: trial and failure of ≥2 systemic therapies for cGVHD
    • Kineret and rheumatologic agents: required prior conventional therapy trials
    • Action: include dates, agents, and reason for discontinuation (failure/intolerance/contraindication)
    Billing Rule

    Medicare Part B vs Part D determination — submit use/setting details

    Coverage determination may depend on Medicare Part B vs Part D. Submit information describing the drug use and clinical setting (e.g., administration site, infused/physician office vs outpatient pharmacy dispensing) so the payer can determine whether the drug is billed under Part B or Part D. Failure to submit setting and use details may delay correct coverage determination.

    • Action: submit documentation of use and setting to determine Part B vs Part D coverage
    • Risk: omission of setting/use details may prevent correct benefit determination
    Documentation Required

    Required diagnostic and prior therapy documentation — mutation testing, microbiology, and disease-specific criteria

    Ensure required diagnostic and treatment history documentation is provided for agents that mandate specific testing or mutation status: examples include Abilify Mycite (diagnosis and prior treatment documentation), Alecensa (document ALK-positive metastatic NSCLC or adjuvant use), Arikayce (sputum cultures and prior therapy documentation), Lynparza and other PARP inhibitors (BRCA/H RR testing and prior chemo/endocrine therapy), Lytgobi (FGFR2 fusion/rearrangement), Piqray (PIK3CA mutation and prior endocrine progression), Rezdiffra (fibrosis stage F2–F3 confirmed by listed tests or biopsy within 12 months), Tibsovo (IDH1 mutation), Trikafta/other CF modulators (CF diagnosis, genotype, age/formulation specifics), Truqap/Tukysa (molecular alterations PIK3CA/AKT1/PTEN; prescriber specialty), and many oncology targeted agents where missing mutation or staging documentation risks denial.

    • Provide diagnostic tests/mutation reports (e.g., ALK, ROS1, EGFR exon 20, FGFR2, BRCA, PIK3CA, IDH1) where required
    • Include prior lines of therapy, dates, and response/progression documentation
    • Cystic fibrosis products: include CF diagnosis and genotype; age/formulation specifics
    • Reauthorization: include clinical response metrics where applicable

    Coding, Billing Notes & Indexed Drug List

    Covered specialty drug products (partial list)mixedCovered
    Exkivitymobocertinib (product name listed as Exkivity)
    Covered specialty drug products (partial list)mixedCovered
    Fasenrabenralizumab (product name listed as Fasenra / Fasenra Pen)
    Finteplafintepla (product name listed)
    Covered specialty drug products (partial list)mixedCovered
    Gavretopralsetinib (Gavreto) listed
    Ibrancepalbociclib (Ibrance) listed
    Coverage setting notemixed
    Medicare Part B or DCoverage may fall under Part B or Part D depending on drug use and setting
    Part B vs Part D notemixed
    No codes listed
    Indexed drug list (partial)mixed
    No codes listed
    Fibrosis stage — Rezdiffra (MASH/NASH)
    Required fibrosis stageF2 or F3
    Confirmation windowFibrosis stage must be confirmed by specified noninvasive tests or liver biopsy within the past 12 months
    Associated diagnosisMASH (metabolic dysfunction-associated steatohepatitis) — formerly NASH
    IgE level — Xolair (omalizumab)
    Required pre-treatment IgE>= 30 IU/mL and <= 1,300 IU/mL
    Indication contextUsed for moderate- to severe persistent asthma with perennial allergen sensitivity
    Prescriber requirementPrescribing physician must be an allergist, dermatologist, immunologist, otolaryngologist, or pulmonologist

    Initial Authorization / First-Line Requirements

    Reauthorization / Continuation Requirements

    Step Therapy / Prior-Therapy Tables

    Step therapy requirementDetails
    Must document trial, failure, contraindication, or intolerance
    For indicated conditions (examples: RA, plaque psoriasis, PJIA) the member must have documentation of a prior trial and either failure of therapy, documented contraindication, or intolerance to the specified prior agent(s).
    Step therapy requirementDetails
    Step through specified topical and/or conventional systemic therapies before biologic approval
    For plaque psoriasis and related dermatology/rheumatology indications: prior failure, contraindication, or intolerance to listed topical agents (eg, medium+ potency topical corticosteroid, vitamin D analog, tazarotene, calcineurin inhibitor, anthralin, coal tar) or conventional systemic therapies (eg, methotrexate, leflunomide, sulfasalazine) is required before biologic authorization.
    Step therapy requirementDetails
    Prior systemic therapy failure required
    Certain systemic indications (examples: chronic graft-versus-host disease, Jakafi entry) require trial and failure of one or more prior systemic therapies before authorization of the requested agent.
    Step therapy requirementDetails
    Trial and failure, contraindication, or intolerance to two specified agents required
    Example (Kineret for RA initial): trial and failure, contraindication, or intolerance to two of the following—etanercept (Enbrel), a formulary adalimumab product, abatacept (Orencia), Rinvoq (upadacitinib), or Xeljanz/XR (tofacitinib)—unless attested inappropriate.
    Step therapy requirementDetails
    Documentation of prior therapy trials as specified per drug
    Several products require documentation of prior therapies per product-specific rules—examples include Lynparza and Nexletol/Nexlizet which require prior use or failure of specified therapies (see product criteria).
    Step therapy requirementDetails
    Document prior therapy and progression or intolerance as specified per product
    For many oncology and specialty agents, the authorization requires submission of prior therapy history and documentation of progression or intolerance to those therapies (examples: Rezurock, other oncology entries).
    Step therapy requirementDetails
    Prior trial or intolerance required
    For certain biologics (example: Stelara) a trial, intolerance, or contraindication to specified prior agents (Yesintek or Steqeyma) is required before authorization.
    Step therapy requirementDetails
    Prior trial required
    Examples include osteoporosis therapies where teriparatide requires inadequate response or intolerance to at least one traditional osteoporosis treatment prior to approval.
    Step therapy requirementDetails
    Prerequisite Part D drug required
    Some product criteria specify a prerequisite Part D drug must have been used prior to authorization (examples: Lynparza, Nexletol/Nexlizet and other listed products that indicate requirement of a Part D prerequisite).
    Step therapy requirementDetails
    Documentation of prior trial and failure/contraindication/intolerance required per drug-specific entry
    Policy requires documentation of prior trials and either failure, contraindication, or intolerance to specified agents for approval—examples include requirements for H. pylori (Voquezna) and various biologic/DMARD entries.
    Step therapy requirementDetails
    Trial and failure or intolerance required before authorizing some biologics
    For multiple immunologic and rheumatologic biologics, authorization is contingent on documented inadequate response or intolerance to TNF inhibitors or conventional DMARDs as specified per indication.

    Site-of-Care & Medicare Part B / Part D Considerations

    Note

    Key Terms & Definitions

    Coverage Duration
    Typical authorization period2 years (commonly stated for most products)
    Exceptions notedSome products specify different durations (e.g., Jynarque: 1 year reauthorization; select agents may list shorter durations)
    ApplicationCoverage duration is listed in individual product entries and may require specific reauthorization criteria
    Non-radiographic axial spondyloarthritis (nr-axSpA)
    DefinitionActive non-radiographic axial spondyloarthritis (nr-axSpA): active disease without definitive radiographic sacroiliac joint structural damage
    Objective signs of inflammationElevated C-reactive protein (CRP) and/or sacroiliitis on MRI
    Prior therapy requirementMinimum one-month trial and failure, contraindication, or intolerance to two NSAIDs at maximally indicated doses for some related entries
    SEGA — TSC-associated subependymal giant cell astrocytoma
    DefinitionSEGA: Subependymal Giant Cell Astrocytoma associated with tuberous sclerosis complex (TSC)
    Surgical candidacyAuthorization requires that the member is not a candidate for surgical resection
    PrescriberPrescribing physician should be a neurologist or oncologist
    RET fusion-positive
    DefinitionRET fusion-positive: tumor harboring RET gene rearrangement (RET fusion) in NSCLC or thyroid cancer
    Therapeutic contextApplies to advanced/metastatic disease requiring systemic therapy; radioactive iodine–refractory status noted for thyroid cancer when appropriate
    PrescriberPrescribing physician must be an oncologist
    Rapidly progressing ADPKD — context for Jynarque (tolvaptan)
    DefinitionRapidly progressing ADPKD: ADPKD judged to be rapidly progressing as specified for Jynarque initiation
    Liver monitoringALT, AST, and bilirubin measured prior to initiation, at 2 and 4 weeks after initiation, then monthly for first 18 months; if on therapy >18 months, at least every 3 months
    Liver function exclusionPatient must not have a history of significant liver impairment or injury (except uncomplicated polycystic liver disease)
    NOMID confirmation — criteria for Kineret
    Confirmation optionsNOMID (neonatal-onset multisystem inflammatory disease) diagnosis confirmed by NLRP3 mutation OR by clinical criteria plus elevated acute phase reactants
    Clinical criteria exampleClinical criteria include two or more features (urticaria-like rash, cold/stress‑triggered episodes, hearing loss, musculoskeletal symptoms, chronic aseptic meningitis, skeletal abnormalities)
    Relevant labsElevated acute phase reactants such as ESR, CRP, or serum amyloid A (SAA)
    HRD-positive — homologous recombination deficiency
    DefinitionHRD-positive: homologous recombination deficiency–positive tumor status used in oncology (eg, ovarian cancer) to define eligibility for specific maintenance regimens
    Clinical useApplied in combination therapy contexts (e.g., maintenance with bevacizumab) where HRD-positive status is required
    DocumentationMutation or genomic testing results required in medical record per indication-specific requirements
    CTEPH — chronic thromboembolic pulmonary hypertension
    DefinitionCTEPH: chronic thromboembolic pulmonary hypertension, including persistent/recurrent disease after surgical treatment or inoperable cases
    Diagnostic confirmationDiagnosis of persistent/recurrent CTEPH after surgery or determination of inoperable status required for authorization
    PrescriberPrescribing physician must be a cardiologist or pulmonologist
    MASH (formerly NASH)
    DefinitionMASH: metabolic dysfunction-associated steatohepatitis (formerly known as NASH)
    Diagnostic contextUsed in criteria for Rezdiffra where staging and absence of cirrhosis are required
    Associated requirementsPresence of ≥1 metabolic risk factor (eg, T2DM, hypertension, obesity) accompanies diagnosis in eligibility criteria
    F508del — CFTR gene mutation
    DefinitionF508del: a specific CFTR gene mutation (ΔF508) relevant to cystic fibrosis therapies
    Genotype documentationHomozygosity for F508del must be documented where required for coverage (eg, certain product entries)
    Therapeutic relevanceSome CFTR modulators are ineffective in patients homozygous for F508del and exclusions are specified
    Opioid tolerant — definition and example doses (TIRF eligibility)
    DefinitionOpioid tolerant: patients taking around-the-clock opioids such as morphine oral ≥60 mg daily, fentanyl transdermal ≥25 mcg/hour, oxycodone oral ≥30 mg daily, hydromorphone oral ≥8 mg daily, or an equianalgesic dose of another opioid daily for a week or longer
    TIRF contextOpioid-tolerant status is required for eligibility for transmucosal immediate-release fentanyl (TIRF) products for breakthrough cancer pain
    Prescriber requirementPrescriber must be an oncologist or pain management specialist and patient must remain on around-the-clock opioids when taking TIRF
    Trial, Failure, Contraindication, or Intolerance (TF/C/I)
    DefinitionTrial, Failure, Contraindication, or Intolerance (TF/C/I): documented trial and either failure of therapy, contraindication to therapy, or intolerance to therapy as specified for prior-therapy requirements
    DocumentationProvider must document prior trials and the reason they failed or were inappropriate (eg, adverse event, contraindication, lack of efficacy)
    ApplicationUsed across many biologic and specialty drug criteria to define prerequisite therapy requirements
    Bismuth quadruple therapy — H. pylori prerequisite
    DefinitionBismuth quadruple therapy: a regimen typically including bismuth, metronidazole, tetracycline, and a proton pump inhibitor used as prerequisite therapy for H. pylori treatment
    Prerequisite roleVoquezna H. pylori packs require trial and failure, contraindication, or intolerance to bismuth quadruple therapy before authorization
    Example agentsTypical components: bismuth + metronidazole + tetracycline + PPI
    Prerequisite Part D drug — definition and usage guidance
    DefinitionPrerequisite Part D drug: an authorization requirement that the member has previously used or failed a specified Part D–covered medication before the requested drug will be authorized
    Usage guidanceSeveral products in this document explicitly require a prerequisite Part D drug (eg, Lynparza, Nexletol/Nexlizet, Truqap entries) and documentation of that prior use must be submitted
    Documentation noteFailure to provide required Part D prior-therapy documentation may lead to denial

    Policy Scope & Background

    This document provides Harvard Pilgrim Health Care prior authorization medical necessity criteria for a broad set of pharmacy and specialty drug products. It defines product-specific coverage conditions, required clinical documentation, prescriber restrictions, prerequisite therapy or Part D prerequisites where applicable, and typical coverage durations used to adjudicate requests for authorization. Examples of drug-specific requirements include diagnosis confirmation, mutation or biomarker test results, prior trial/failure or intolerance to specified therapies, and site-of-care or usage details needed to determine Medicare Part B versus Part D coverage.

    The scope of products covered ranges across oncology, immunology/biologics, pulmonary hypertension, cystic fibrosis, infectious disease, neurology, hematology, and other specialty categories. For many entries the policy specifies that the prescribing clinician should be a relevant specialist (for example, oncologist, rheumatologist, pulmonologist, neurologist, or allergist) and notes typical authorization periods (commonly 2 years, with specific exceptions such as certain agents having 1-year initial coverage).

    The policy framework requires submission of the required medical information listed for each product (for example: documented diagnosis, relevant genetic or laboratory testing, documentation of prior therapies and responses, and monitoring plans for agents with safety lab requirements). Requests missing required diagnostic confirmation, prior-therapy documentation, or information about the drug use/setting (when needed to determine Part B vs Part D) may be denied or returned for clarification.

    Providers should consult the product-specific criteria in this section when preparing prior authorization requests so that the submitted documentation demonstrates that all of the listed medical necessity conditions for the requested indication are satisfied. Where indicated, step-therapy or prerequisite Part D drug requirements, explicit exclusions (for example, non‑approved uses), and reauthorization/continuation criteria (including demonstration of clinical response) are specified and must be met for approval.

    Revision History & Effective Dates

    2026-06-01Policy effectiveLatest

    Policy effective date published as June 1, 2026.